Workup for Strong Family History of PE in Multiple First-Degree Relatives
For asymptomatic patients with a strong family history of PE in multiple first-degree relatives, test for heritable thrombophilias including Factor V Leiden (FVL), prothrombin (PT) G20210A mutation, antithrombin deficiency, Protein C deficiency, Protein S deficiency, and consider testing for antiphospholipid antibodies. 1
Rationale for Thrombophilia Testing
The presence of multiple first-degree relatives with PE substantially increases the patient's lifetime risk of venous thromboembolism (VTE). Family history of VTE increases the odds of PE by 1.51-fold in symptomatic patients 2, and siblings with two affected family members have a dramatically elevated standardized incidence ratio of 114.29 (95% CI, 56.57-223.95) for PE 3. This strong familial clustering suggests underlying genetic thrombophilias that warrant investigation.
Comprehensive Thrombophilia Panel
The laboratory evaluation should include:
- Factor V Leiden mutation testing (most common heritable thrombophilia, present in 15-20% of VTE cases) 1
- Prothrombin G20210A mutation 1
- Antithrombin deficiency 1
- Protein C deficiency 1
- Protein S deficiency 1
- Lupus anticoagulant 1
- Anticardiolipin antibodies 1
- Anti-β2-glycoprotein-1 antibodies 1
- Factor VIII levels 1
Critical Findings That Alter Management
Homozygous Factor V Leiden
If homozygous FVL is identified, the annual risk for initial VTE is approximately 180 per 10,000 per year—an 18-fold increase compared to relatives without the mutation 1. This represents a sufficiently high risk that preemptive anticoagulation should be considered, though no formal outcome studies exist for asymptomatic patients 1.
Heterozygous Factor V Leiden
Single FVL variant (heterozygosity) increases risk for initial VTE by 4- to 7-fold, with an annual incidence of 0.41% among carriers versus 0.19% among non-carriers in first-degree relatives of young VTE patients 1. However, routine anticoagulation is not recommended for asymptomatic heterozygous carriers due to unfavorable benefit-to-harm ratio—the risk of major bleeding from anticoagulation (1-3% per year) exceeds the thrombotic risk by at least threefold 1.
When NOT to Anticoagulate
Do not initiate prophylactic anticoagulation in asymptomatic family members with heterozygous FVL or PT mutations. 1 The bleeding risk from warfarin therapy (at least 100 per 10,000 patient-years) substantially exceeds the thrombotic risk in these individuals 1.
Situational Prophylaxis Considerations
For identified mutation carriers, consider short-term prophylactic anticoagulation during high-risk periods:
- Major surgery 1
- Prolonged immobilization 1
- Pregnancy and postpartum period 1
- Estrogen-containing contraceptive use (which should generally be avoided) 1
Counseling First-Degree Relatives
Inform first-degree relatives that family history of VTE is a significant risk factor (1.51-fold increased odds) 2, and they should:
- Report family history when presenting with chest pain or dyspnea, as this increases likelihood of PE diagnosis (3.2% vs 1.6% in those without family history) 4
- Avoid modifiable risk factors including estrogen-containing contraceptives and hormone replacement therapy 1
- Seek immediate evaluation for symptoms of PE (sudden dyspnea, pleuritic chest pain, syncope, hemoptysis) 5
- Use prophylactic anticoagulation during high-risk situations (surgery, prolonged travel, immobilization) 1
Common Pitfalls to Avoid
Do not test for thrombophilias during acute VTE or while on anticoagulation, as results may be falsely abnormal (particularly Protein C, Protein S, and antithrombin levels) 1. Testing should be performed at least 2-4 weeks after completing anticoagulation.
Do not use thrombophilia testing results to determine duration of anticoagulation after a first unprovoked VTE—the decision for long-term anticoagulation should be based on bleeding risk, not mutation status 1. Both carriers and non-carriers benefit similarly from extended anticoagulation after unprovoked VTE 1.